Get the Stockscreener App
10.89
0.18%
0.02
Evolus Inc stock is traded at $10.89, with a volume of 916.60K.
It is up +0.18% in the last 24 hours and down -13.78% over the past month.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.
See More
Previous Close:
$10.87
Open:
$10.74
24h Volume:
916.60K
Relative Volume:
1.52
Market Cap:
$689.57M
Revenue:
$202.09M
Net Income/Loss:
$-61.69M
P/E Ratio:
-9.3077
EPS:
-1.17
Net Cash Flow:
$-35.64M
1W Performance:
-5.39%
1M Performance:
-13.78%
6M Performance:
+1.11%
1Y Performance:
+12.50%
1-Day Range:
$10.73
$11.16
1-Week Range:
$10.64
$11.83
52-Week Range:
$9.70
$17.82
Evolus Inc Stock (EOLS) Company Profile
Name
Evolus Inc
Sector
Phone
(949) 284-4555
Address
520 NEWPORT CENTER DRIVE, NEWPORT BEACH
Compare EOLS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EOLS
Evolus Inc
|
10.89 | 689.57M | 202.09M | -61.69M | -35.64M | -1.08 |
|
ZTS
Zoetis Inc
|
164.84 | 74.37B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.69 | 43.81B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.10 | 41.53B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
22.09 | 25.03B | 16.77B | -959.00M | 1.37B | -0.85 |
|
VTRS
Viatris Inc
|
12.52 | 14.94B | 15.05B | -883.30M | 1.89B | -0.74 |
Evolus Inc Stock (EOLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Jun-23-22 | Initiated | Needham | Buy |
| May-12-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-20-22 | Upgrade | Truist | Hold → Buy |
| May-06-21 | Upgrade | Mizuho | Neutral → Buy |
| Apr-08-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-24-21 | Downgrade | Truist | Buy → Hold |
| Jul-07-20 | Downgrade | Mizuho | Buy → Neutral |
| Feb-06-20 | Resumed | Mizuho | Buy |
| Nov-26-19 | Initiated | SVB Leerink | Outperform |
| Sep-05-19 | Resumed | Mizuho | Buy |
| Jun-28-19 | Initiated | Wells Fargo | Market Perform |
| Jun-11-19 | Initiated | Barclays | Underweight |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Feb-14-19 | Initiated | H.C. Wainwright | Buy |
| Jan-29-19 | Initiated | Stifel | Buy |
View All
Evolus Inc Stock (EOLS) Latest News
Evolus, Inc.'s (NASDAQ:EOLS) Path To Profitability - Yahoo Finance
Lord Abbett & CO. LLC Acquires 188,685 Shares of Evolus, Inc. (NASDAQ:EOLS) - MarketBeat
Stock Options Galore! Discover Evolus’ Latest Move - Jomfruland.net
(EOLS) On The My Stocks Page - Stock Traders Daily
Evolus Expands Team with Strategic Equity Incentives Package for 20 New Hires - StockTitan
Evolus's SWOT analysis: aesthetics firm's stock poised for growth By Investing.com - Investing.com South Africa
Evolus's SWOT analysis: aesthetics firm's stock poised for growth - Investing.com
Charles Schwab Investment Management Inc. Buys 265,635 Shares of Evolus, Inc. (NASDAQ:EOLS) - MarketBeat
Evolus, Inc. (NASDAQ:EOLS) Is Expected To Breakeven In The Near Future - Simply Wall St
212,209 Shares in Evolus, Inc. (NASDAQ:EOLS) Acquired by Walleye Capital LLC - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Takes $940,000 Position in Evolus, Inc. (NASDAQ:EOLS) - MarketBeat
Great Point Partners LLC Has $18.95 Million Stock Holdings in Evolus, Inc. (NASDAQ:EOLS) - MarketBeat
Jeffrey Plumer: Defending a ‘Whole New World’ - Orange County Business Journal
When (EOLS) Moves Investors should Listen - Stock Traders Daily
Here's Why Evolus (EOLS) Could be Great Choice for a Bottom Fisher - MSN
Evolus, Inc. (NASDAQ:EOLS) Short Interest Up 8.8% in October - MarketBeat
OC500 2024: Sandra Beaver - Orange County Business Journal
Behind the Bell: Evolus - Nasdaq
Perceptive Advisors LLC Adjusts Stake in Evolus Inc - GuruFocus.com
Down -29.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Evolus (EOLS) - Yahoo Finance
Stonepine Capital Management Reduces Stake in Evolus Inc - GuruFocus.com
Evolus, Inc. (NASDAQ:EOLS) Might Not Be As Mispriced As It Looks After Plunging 26% - Simply Wall St
Evolus, Inc. (NASDAQ:EOLS) Position Increased by GSA Capital Partners LLP - MarketBeat
Evolus Inc (EOLS) Shares Gap Down to $12.58 on Nov 12 - GuruFocus.com
Evolus Third Quarter 2024 Earnings: Misses Expectations - Simply Wall St
Evolus, Inc. (EOLS) Reports Q3 Loss, Misses Revenue Estimates - MSN
Earnings Update: Evolus, Inc. (NASDAQ:EOLS) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts - Yahoo Finance
Evolus, Inc. (NASDAQ:EOLS) Q3 2024 Earnings Call Transcript - Insider Monkey
Evolus Inc (EOLS) Q3 2024 Earnings Call Highlights: Revenue Surge Amid Market Challenges By GuruFocus - Investing.com Canada
Evolus (NASDAQ:EOLS) Shares Gap Down on Disappointing Earnings - MarketBeat
Evolus' (EOLS) Buy Rating Reiterated at HC Wainwright - MarketBeat
Evolus Inc (EOLS) Q3 2024 Earnings Call Highlights: Revenue Surge Amid Market Challenges - GuruFocus.com
Evolus earnings missed by $0.18, revenue fell short of estimates - Investing.com Canada
Evolus, Inc. Reports Strong Q3 2024 Growth - TipRanks
Evolus Reports Third Quarter 2024 Results - Business Wire
Injections For Your Frown Lines Cost Just $49, Thanks To This Membership Club - The Zoe Report
Prescription Hair Loss and Hair Removal Drugs Market Projected To Witness Substantial Growth, 2024-2031: - EIN News
Evolus receives nod from EU for hyaluronic acid injectables, anticipates US approval - Healio
Evolus (NASDAQ:EOLS) Earns "Buy" Rating from HC Wainwright - MarketBeat
Evolus to Participate in Stifel 2024 Healthcare Conference - The Bakersfield Californian
Evolus, Inc. (NASDAQ:EOLS) Shares Purchased by Rice Hall James & Associates LLC - MarketBeat
Objective long/short (EOLS) Report - Stock Traders Daily
Evolus, Inc. Announces EU Approval of Estyme Injectable Hyaluronic Acid Gels Under New Medical Device Regulation - Marketscreener.com
Evolus Gets EU Approval for Treatment of Wrinkles - MarketWatch
Evolus gains EU certification for new dermal filler products - Investing.com
Evolus gains EU certification for new dermal filler products By Investing.com - Investing.com UK
Evolus Inc Stock (EOLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.61%
1.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):